Lista de obras - Paul A Clarke - Dominio Público Uruguay

A PI3K- and GTPase-independent Rac1-mTOR mechanism mediates MET-driven anchorage-independent cell growth but not migration

artículo científico publicado en 2020

A genome-scale CRISPR screen identifies the ERBB and mTOR signalling networks as key determinants of response to PI3K inhibition in pancreatic cancer

artículo científico publicado en 2020

A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease.

artículo científico publicado en 2015

ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system

artículo científico publicado en 2013

Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1

artículo científico publicado en 2002

Antisense treatment directed against mutated Ki-ras in human colorectal adenocarcinoma

artículo científico publicado en 2001

Apoptosis is associated with triacylglycerol accumulation in Jurkat T-cells

artículo científico publicado en 2002

Assessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinases

artículo científico publicado en 2016

BCL-2 antisense therapy in patients with non-Hodgkin lymphoma

artículo científico publicado en 1997

Bcl-2 expression and response to chemotherapy in colorectal adenocarcinomas.

artículo científico publicado en 1997

Binding of Epstein-Barr virus small RNA EBER-1 to the double-stranded RNA-activated protein kinase DAI.

artículo científico publicado en 1991

CHK1 inhibition is synthetically lethal with loss of B-family DNA polymerase function in human lung and colorectal cancer cells

artículo científico publicado en 2020

Combining trail with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling

artículo científico publicado en 2013

Correction: Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases

artículo científico publicado en 2020

Correlation of overall survival with gene expression profiles in a prospective study of resectable esophageal cancer

artículo científico publicado en 2011

Death by chaperone: HSP90, HSP70 or both?

artículo científico publicado en 2009

Demonstrating In-Cell Target Engagement Using a Pirin Protein Degradation Probe (CCT367766).

artículo científico publicado en 2017

Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.

artículo científico publicado en 2015

Discovery of small molecule cancer drugs: Successes, challenges and opportunities ⬇️

artículo científico publicado el 3 de marzo de 2012

Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer

artículo científico publicado en 2019

Drugging PI3K in cancer: refining targets and therapeutic strategies

artículo científico

Drugging the PI3 kinome

artículo científico publicado en 2006

Drugging the PI3 kinome: from chemical tools to drugs in the clinic.

artículo científico publicado en 2010

Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis

artículo científico publicado en 2008

E3 ubiquitin ligase Cullin-5 modulates multiple molecular and cellular responses to heat shock protein 90 inhibition in human cancer cells

artículo científico publicado en 2014

Epstein-Barr virus gene expression in interferon-treated cells. Implications for the regulation of protein synthesis and the antiviral state

artículo científico publicado en 1990

Expression of genes for the Epstein-Barr virus small RNAs EBER-1 and EBER-2 in Daudi Burkitt's lymphoma cells: effects of interferon treatment

artículo científico publicado en 1992

Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer

artículo científico publicado en 2020

First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors

artículo científico publicado en 2015

Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin.

artículo científico publicado en 2007

Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential.

artículo científico publicado en 2001

Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone.

artículo científico publicado en 2000

Genes and Proteins Governing the Cellular Sensitivity to HSP90 Inhibitors: A Mechanistic Perspective ⬇️

artículo científico publicado el 1 de octubre de 2003

Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology

artículo científico

HSF1 in Translation

artículo científico publicado en 2013

Hsp90-dependent activation of protein kinases is regulated by chaperone-targeted dephosphorylation of Cdc37.

artículo científico publicado en 2008

Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis.

artículo científico publicado en 2001

Interactions between the double-stranded RNA binding motif and RNA: definition of the binding site for the interferon-induced protein kinase DAI (PKR) on adenovirus VA RNA.

artículo científico publicado en 1995

Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study

artículo científico publicado en 1998

Labeling and purification of RNA synthesized by in vitro transcription

scientific article published on 01 January 1999

Lactate and choline metabolites detected in vitro by nuclear magnetic resonance spectroscopy are potential metabolic biomarkers for PI3K inhibition in pediatric glioblastoma

artículo científico publicado en 2014

MIR21 drives resistance to Heat Shock Protein 90 inhibition in cholangiocarcinoma

artículo científico publicado en 2017

Magnetic resonance detects metabolic changes associated with chemotherapy-induced apoptosis

artículo científico publicado en 1999

Mode of cell death induced by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic BAX.

artículo científico publicado en 2013

Molecular pharmacology of cancer therapy in human colorectal cancer by gene expression profiling.

artículo científico publicado en 2003

Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma

artículo científico publicado en 2009

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.

artículo científico publicado en 2018

Personalized medicine: patient-predictive panel power

artículo científico publicado en 2012

Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.

artículo científico publicado en 2007

Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors

artículo científico publicado en 2009

Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trials

scientific article published on 12 December 2011

Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer.

artículo científico publicado en 2001

Preparation and evaluation of trisubstituted pyrimidines as phosphatidylinositol 3-kinase inhibitors. 3-Hydroxyphenol analogues and bioisosteric replacements

artículo científico publicado en 2010

Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors ⬇️

artículo científico publicado el 1 de enero de 2011

RNA footprinting and modification interference analysis

artículo científico publicado en 1999

Resisting targeted therapy: fifty ways to leave your EGFR

scientific article published on 01 April 2011

Restricting direct interaction of CDC37 with HSP90 does not compromise chaperoning of client proteins

artículo científico publicado en 2013

Sensitization of (colon) cancer cells to death receptor related therapies: a report from the FP6-ONCODEATH research consortium

artículo científico

Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases

scientific article published on 12 July 2019

Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors

artículo científico publicado en 2008

Small-molecule targeting of brachyury transcription factor addiction in chordoma

scientific article published on 21 January 2019

Surprising specificity of PKR binding to delta agent genomic RNA.

artículo científico publicado en 1997

The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.

artículo científico publicado en 2012

The discovery of potent ribosomal S6 kinase inhibitors by high-throughput screening and structure-guided drug design

artículo científico publicado en 2013

The expanding proteome of the molecular chaperone HSP90.

artículo científico publicado en 2012

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

artículo científico publicado en 2008

The kinase polypharmacology landscape of clinical PARP inhibitors

scientific article published on 17 February 2020

The off-target kinase landscape of clinical PARP inhibitors

The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy.

artículo científico publicado en 2010

Translational control by the Epstein-Barr virus small RNA EBER-1. Reversal of the double-stranded RNA-induced inhibition of protein synthesis in reticulocyte lysates

artículo científico publicado en 1990

Lista de obras de Paul A Clarke

A PI3K- and GTPase-independent Rac1-mTOR mechanism mediates MET-driven anchorage-independent cell growth but not migration

A genome-scale CRISPR screen identifies the ERBB and mTOR signalling networks as key determinants of response to PI3K inhibition in pancreatic cancer

A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease.

ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system

Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1

Antisense treatment directed against mutated Ki-ras in human colorectal adenocarcinoma

Apoptosis is associated with triacylglycerol accumulation in Jurkat T-cells

Assessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinases

BCL-2 antisense therapy in patients with non-Hodgkin lymphoma

Bcl-2 expression and response to chemotherapy in colorectal adenocarcinomas.

Binding of Epstein-Barr virus small RNA EBER-1 to the double-stranded RNA-activated protein kinase DAI.

CHK1 inhibition is synthetically lethal with loss of B-family DNA polymerase function in human lung and colorectal cancer cells

Combining trail with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling

Correction: Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases

Correlation of overall survival with gene expression profiles in a prospective study of resectable esophageal cancer

Death by chaperone: HSP90, HSP70 or both?

Demonstrating In-Cell Target Engagement Using a Pirin Protein Degradation Probe (CCT367766).

Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.

Discovery of small molecule cancer drugs: Successes, challenges and opportunities ⬇️

Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer

Drugging PI3K in cancer: refining targets and therapeutic strategies

Drugging the PI3 kinome

Drugging the PI3 kinome: from chemical tools to drugs in the clinic.

Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis

E3 ubiquitin ligase Cullin-5 modulates multiple molecular and cellular responses to heat shock protein 90 inhibition in human cancer cells

Epstein-Barr virus gene expression in interferon-treated cells. Implications for the regulation of protein synthesis and the antiviral state

Expression of genes for the Epstein-Barr virus small RNAs EBER-1 and EBER-2 in Daudi Burkitt's lymphoma cells: effects of interferon treatment

Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer

First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors

Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin.

Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential.

Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone.

Genes and Proteins Governing the Cellular Sensitivity to HSP90 Inhibitors: A Mechanistic Perspective ⬇️

Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology

HSF1 in Translation

Hsp90-dependent activation of protein kinases is regulated by chaperone-targeted dephosphorylation of Cdc37.

Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis.

Interactions between the double-stranded RNA binding motif and RNA: definition of the binding site for the interferon-induced protein kinase DAI (PKR) on adenovirus VA RNA.

Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study

Labeling and purification of RNA synthesized by in vitro transcription

Lactate and choline metabolites detected in vitro by nuclear magnetic resonance spectroscopy are potential metabolic biomarkers for PI3K inhibition in pediatric glioblastoma

MIR21 drives resistance to Heat Shock Protein 90 inhibition in cholangiocarcinoma

Magnetic resonance detects metabolic changes associated with chemotherapy-induced apoptosis

Mode of cell death induced by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic BAX.

Molecular pharmacology of cancer therapy in human colorectal cancer by gene expression profiling.

Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.

Personalized medicine: patient-predictive panel power

Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.

Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors

Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trials

Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer.

Preparation and evaluation of trisubstituted pyrimidines as phosphatidylinositol 3-kinase inhibitors. 3-Hydroxyphenol analogues and bioisosteric replacements

Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors ⬇️

RNA footprinting and modification interference analysis

Resisting targeted therapy: fifty ways to leave your EGFR

Restricting direct interaction of CDC37 with HSP90 does not compromise chaperoning of client proteins

Sensitization of (colon) cancer cells to death receptor related therapies: a report from the FP6-ONCODEATH research consortium

Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases

Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors

Small-molecule targeting of brachyury transcription factor addiction in chordoma

Surprising specificity of PKR binding to delta agent genomic RNA.

The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.

The discovery of potent ribosomal S6 kinase inhibitors by high-throughput screening and structure-guided drug design

The expanding proteome of the molecular chaperone HSP90.

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

The kinase polypharmacology landscape of clinical PARP inhibitors

The off-target kinase landscape of clinical PARP inhibitors

The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy.

Translational control by the Epstein-Barr virus small RNA EBER-1. Reversal of the double-stranded RNA-induced inhibition of protein synthesis in reticulocyte lysates